Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

DPI-386

Aliases
DPI-386 Nasal Gel, scopolamine
Name
scopolamine
INN Name
scopolamine
FDA Approved
Yes

3 clinical trials

3 organizations

4 indications

1 document

Indication
Motion Sickness
Indication
Space
Indication
Motion Simulation
Indication
Parabolic Flight
Clinical trial
Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Field Test
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Status: Completed, Estimated PCD: 2022-11-29
Organization
Ingenus Pharmaceuticals, LLC
Organization
A-S Medication Solutions
Document
DailyMed Label: scopolamine
Organization
Actavis Pharma, Inc.